MX354579B - Anillo vaginal que comprende meloxicam y un agente modulador de la liberacion del principio activo, util como anticonceptivo de uso continuo en mujeres. - Google Patents

Anillo vaginal que comprende meloxicam y un agente modulador de la liberacion del principio activo, util como anticonceptivo de uso continuo en mujeres.

Info

Publication number
MX354579B
MX354579B MX2014007523A MX2014007523A MX354579B MX 354579 B MX354579 B MX 354579B MX 2014007523 A MX2014007523 A MX 2014007523A MX 2014007523 A MX2014007523 A MX 2014007523A MX 354579 B MX354579 B MX 354579B
Authority
MX
Mexico
Prior art keywords
release
active principle
women
modulating
continuous
Prior art date
Application number
MX2014007523A
Other languages
English (en)
Other versions
MX2014007523A (es
Inventor
Chen Shu-Chen
Del Carmen Beltran Apablaza Marianela
Original Assignee
Laboratorios Andromaco S A Ex Inversiones Gruchi S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Andromaco S A Ex Inversiones Gruchi S A filed Critical Laboratorios Andromaco S A Ex Inversiones Gruchi S A
Publication of MX2014007523A publication Critical patent/MX2014007523A/es
Publication of MX354579B publication Critical patent/MX354579B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al Anillo vaginal de liberación sostenida que comprende meloxicam y un agente modulador de la liberación del principio activo, tal como polivinilpirrolidona K-30, que libera el principio activo por al menos 90 días, útil como anticonceptivo de uso continuo en mujeres. El anillo vaginal comprende preferentemente 5% a 30% en peso de meloxicam, en relación al peso total de la formulación.
MX2014007523A 2011-12-29 2011-12-29 Anillo vaginal que comprende meloxicam y un agente modulador de la liberacion del principio activo, util como anticonceptivo de uso continuo en mujeres. MX354579B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2011/056022 WO2013098591A1 (es) 2011-12-29 2011-12-29 Anillo vaginal que comprende meloxicam y un agente modulador de la liberación del principio activo, útil como anticonceptivo de uso continuo en mujeres

Publications (2)

Publication Number Publication Date
MX2014007523A MX2014007523A (es) 2014-08-27
MX354579B true MX354579B (es) 2018-03-12

Family

ID=48696404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007523A MX354579B (es) 2011-12-29 2011-12-29 Anillo vaginal que comprende meloxicam y un agente modulador de la liberacion del principio activo, util como anticonceptivo de uso continuo en mujeres.

Country Status (11)

Country Link
US (1) US9533050B2 (es)
EP (1) EP2799043B1 (es)
JP (1) JP5902318B2 (es)
KR (1) KR101785414B1 (es)
CN (1) CN104203169B (es)
BR (1) BR112014015053A2 (es)
CA (1) CA2860108C (es)
EA (1) EA027564B1 (es)
MX (1) MX354579B (es)
NI (1) NI201400066A (es)
WO (1) WO2013098591A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20155779A (fi) 2015-10-30 2017-05-01 Solani Therapeutics Ltd Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu
EP3272333A1 (en) 2016-07-22 2018-01-24 Chemo Research, S.L. Vaginal composition comprising a combination of estrogen and vitamin d

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031631A1 (en) 1996-02-27 1997-09-04 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions
DE19608423A1 (de) 1996-03-05 1997-09-11 Merck Patent Gmbh Implantate mit phasenweiser Arzneistoffabgabe
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6905701B2 (en) * 1997-06-11 2005-06-14 Umd, Inc. Formulations for transmucosal vaginal delivery of bisphosphonates
US20050276836A1 (en) * 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
CN1536986B (zh) 2001-03-27 2012-07-04 沃纳奇尔科特(爱尔兰)有限公司 用于抗微生物剂给药的阴道内药物递送装置
US7004171B2 (en) 2002-02-25 2006-02-28 Hi-Gienic Intra Vaginal Technologies Ltd. System for transvaginal drug delivery
KR20040092649A (ko) 2003-04-24 2004-11-04 엘지전자 주식회사 광디스크의 복사 방지 정보 관리방법
BRPI0513141A (pt) * 2004-07-09 2008-04-29 Population Council Inc composição para anel vaginal, e, processo de contracepção a longo prazo
DE102006027793A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Opioid-Kombinations-Wafer
WO2007150075A2 (en) * 2006-06-23 2007-12-27 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US20080026054A1 (en) * 2007-04-27 2008-01-31 Nectid Inc. Novel anelgesic combination
WO2010009335A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders

Also Published As

Publication number Publication date
EP2799043A1 (en) 2014-11-05
WO2013098591A1 (es) 2013-07-04
EA201491167A1 (ru) 2014-12-30
JP2015503544A (ja) 2015-02-02
KR20140112040A (ko) 2014-09-22
BR112014015053A2 (pt) 2017-06-13
CA2860108C (en) 2016-10-04
NI201400066A (es) 2017-03-13
CN104203169B (zh) 2016-07-13
KR101785414B1 (ko) 2017-10-16
CA2860108A1 (en) 2013-07-04
JP5902318B2 (ja) 2016-04-13
EP2799043B1 (en) 2019-11-27
CN104203169A (zh) 2014-12-10
MX2014007523A (es) 2014-08-27
EA027564B1 (ru) 2017-08-31
EP2799043A4 (en) 2015-08-05
US9533050B2 (en) 2017-01-03
US20150328319A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
MX2012015187A (es) Metodo para suministrar un agente activo.
EA201291372A1 (ru) Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
CU24065B1 (es) Forma de dosificación farmacéutica que comprende nifedipino y un antagonista de angiotensina ii
IN2012MN02923A (es)
NZ602111A (en) Extended release formulations of rasagiline and uses thereof
PH12015501096A1 (en) Composition for immediate and extended release
IN2014KN02324A (es)
MY159492A (en) Solid pharmaceutical formulation with delayed release
PH12015501982A1 (en) Pharmaceutical compositions comprising everolimus
TN2015000135A1 (en) Modified release formulations for oprozomib
MY191875A (en) Solid dosage form
NZ714288A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MD4563C1 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
EP2575842A4 (en) COMPOSITION COMPRISING THE EXTRACT OF PHYSALIS ALKEKENGI VAR. FRANCHETI HORT AS AN ACTIVE INGREDIENT FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO
WO2014056824A3 (en) Oral care composition
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.
WO2012064302A3 (en) Improved montelukast formulations
GEP201706696B (en) Method for treating gynecological diseases
MX354579B (es) Anillo vaginal que comprende meloxicam y un agente modulador de la liberacion del principio activo, util como anticonceptivo de uso continuo en mujeres.
MX2017007856A (es) Composicion para el cuidado bucal.
IN2012CH05549A (es)
RS53086B (en) OLMESARTAN PHARMACEUTICAL COMPOSITIONS
IN2014CN04119A (es)

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: LABORATORIOS ANDROMACO, S.A. (EX INVERSIONES GRUCH

FG Grant or registration